P130. Endoscopic Beating-Heart Tricuspid Valve Surgery Without Jugular Cannulation or Caval Snaring: Clinical Outcomes Using Novel Percutaneous Venous Cannulation
Presented During: Adult Cardiac Poster Session II
Heinrich-Heine University Dusseldorf
Dusseldorf
Germany - Contact Me
Diyar Saeed, MD, PhD is Professor of Cardiac Surgery, Assistant Director of Cardiac Surgery and Director of the MCS and Heart Transplantation Program at Leipzig Heart Center in Leipzig, Germany. Prof. Saeed graduated in 2000 as a medical doctor. He finished his cardiac surgery training at Bad Oeynhausen Heart Center, Germany, Northwestern University, Chicago and Düsseldorf University, Germany. Further , during his residency, he spent 2 years as a postdoctoral Research Fellow at Cleveland Clinic Foundation, Cleveland, OH. Dr. Saeed’s areas of interest are minimal invasive mitral and aortic valve surgeries, minimal invasive /off-pump coronary surgery, heart failure surgery (MCS systems and heart transplantation) and complex redo cardiac procedures.
Monday, May 4, 2026: 9:00 AM - 4:00 PM
McCormick Place Lakeside Center
Room: Exhibit Hall, Poster Area
Description
Objectives:
Endoscopic beating-heart tricuspid valve (TV) surgery is increasingly used in cardiac surgery due to improved postoperative outcomes. Traditional approaches require jugular vein cannulation and total CPB with bicaval cannulation. Caval snaring is always required during beating heart TV surgery to avoid air lock. We present our single-center experience using a percutaneously placed novel venous cannula (Smart Canula), allowing minimal invasive TV surgery without additional jugular cannulation and/or caval snaring.The cannula resembles a stent and has multiple penetrations (Figure 1), making air lock a rare occurrence.
Methods:
Thirteen patients underwent beating-heart TV surgery. Preoperative AF was present in 10 patients (six paroxysmal, two persistent, two permanent). Eight patients (mean age 72 ± 10 years; 6 female gender) received a 680 mm cannula, and five (mean age 64 ± 8 years; 2 female gender) a 720 mm cannula. Three patients underwent isolated tricuspid procedures; the remainder had concomitant procedures, including mitral reconstruction in 69 %, cryoablation in 62 %, LAA exclusion in 46 %, and single cases of ASD closure. Three patients underwent redo surgeries after previous cardiac procedures. Mean procedure time was 305 ± 153 min, mean aortic cross-clamp 56 ± 37 min. Tricuspid repair using the clover technique was performed in four patients.
Results:
All procedures were completed without intraoperative air lock. Complications included one re-exploration for bleeding and one intraoperative conversion to sternotomy. Median ICU stay was 5 days, mean hospital stay 17 ± 5 days. Pacemaker implantation was necessary in two patients. Postoperative echocardiography at discharge showed tricuspid valve regurgitation Grade 0 in 45 %, Grade I in 45 %, and Grade II in 18 %. In-hospital mortality was 0 %.
Conclusion:
Endoscopic beating-heart tricuspid repair can be safely performed using a novel percutaneous cannula, eliminating the need for jugular cannulation and/or total CPB with bicaval snaring. No air lock or cannula related complications was observed.
Authors
Diyar Saeed (1), Orestis Mallis Kyriakides (2), Feras Kabbesh (2), hamid Naraghi (2), Mohamed Zeriouh (2), Andreas Däuwel (2), Bujar Maxhera (2), Diyar Saeed (2)
Institutions
(1) Heinrich-Heine University Dusseldorf, Krefeld, Germany, (2) Health and Medical University Krefeld, Krefeld, Germany
Endoscopic beating-heart tricuspid valve (TV) surgery is increasingly used in cardiac surgery due to improved postoperative outcomes. Traditional approaches require jugular vein cannulation and total CPB with bicaval cannulation. Caval snaring is always required during beating heart TV surgery to avoid air lock. We present our single-center experience using a percutaneously placed novel venous cannula (Smart Canula), allowing minimal invasive TV surgery without additional jugular cannulation and/or caval snaring.The cannula resembles a stent and has multiple penetrations (Figure 1), making air lock a rare occurrence.
Methods:
Thirteen patients underwent beating-heart TV surgery. Preoperative AF was present in 10 patients (six paroxysmal, two persistent, two permanent). Eight patients (mean age 72 ± 10 years; 6 female gender) received a 680 mm cannula, and five (mean age 64 ± 8 years; 2 female gender) a 720 mm cannula. Three patients underwent isolated tricuspid procedures; the remainder had concomitant procedures, including mitral reconstruction in 69 %, cryoablation in 62 %, LAA exclusion in 46 %, and single cases of ASD closure. Three patients underwent redo surgeries after previous cardiac procedures. Mean procedure time was 305 ± 153 min, mean aortic cross-clamp 56 ± 37 min. Tricuspid repair using the clover technique was performed in four patients.
Results:
All procedures were completed without intraoperative air lock. Complications included one re-exploration for bleeding and one intraoperative conversion to sternotomy. Median ICU stay was 5 days, mean hospital stay 17 ± 5 days. Pacemaker implantation was necessary in two patients. Postoperative echocardiography at discharge showed tricuspid valve regurgitation Grade 0 in 45 %, Grade I in 45 %, and Grade II in 18 %. In-hospital mortality was 0 %.
Conclusion:
Endoscopic beating-heart tricuspid repair can be safely performed using a novel percutaneous cannula, eliminating the need for jugular cannulation and/or total CPB with bicaval snaring. No air lock or cannula related complications was observed.
Authors
Diyar Saeed (1), Orestis Mallis Kyriakides (2), Feras Kabbesh (2), hamid Naraghi (2), Mohamed Zeriouh (2), Andreas Däuwel (2), Bujar Maxhera (2), Diyar Saeed (2)
Institutions
(1) Heinrich-Heine University Dusseldorf, Krefeld, Germany, (2) Health and Medical University Krefeld, Krefeld, Germany
Presentation Duration
There is no formal presentation for posters. Your poster will be on display on your assigned day from 9:00AM - 4:00PM
View Submission
ADULT CARDIAC
Innovations: New devices or novel approaches, preclinical or clinical